US FDA Commissioner Nominee Not ‘Pro-Industry Choice,’ GLP-1 Compounding Could Be First Clash

 
• By Sarah Karlin-Smith
  
Marty Makary
Martin Makary testifies at a Senate roundtable in September. (Screenshot)

More from Leadership

More from Scrip